NCT00927732 - Hydroquinidine Versus Placebo in Patients With Brugada Syndrome | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

October 31, 2014

Study Completion Date

October 31, 2014

Conditions

Brugada Syndrome

Interventions

DRUG

hydroquinidine

capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization

DRUG

placebo (sugar)

capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine

Trial Locations (17)

13

AP-HM Marseille, Marseille

29

CHU Brest, Brest

31

CHU Toulouse, Toulouse

33

CHU Bordeaux, Bordeaux

34

CHU Montpellier, Montpellier

35

CHU Rennes, Rennes

37

CHU Tours, Tours

38

CHU Grenoble, Grenoble

49

CHU Angers, Angers

54

CHU Nancy, Nancy

59

CHRU Lille, Lille

67

CHU Strasbourg, Strasbourg

69

CHU Lyon, Lyon

75

AP-HP Paris Lariboisière, Paris

80

CHU Amiens, Amiens

86

CHU Poitiers, Poitiers

44093

CHU Nantes, Nantes